Merck Subsidiary Seeks Expanded Operations in Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
Merck Serono International plans several projects this year to expand its presence in the Japanese market, including beginning trials in the country for a new cancer drug developed in Japan. The subsidiary of German-based Merck KgaA says it will file soon for approval of its Gonal-f (follitropin alfa/beta) fertility treatment that relies on gene-splicing technology. The company also expects approval for marketing its Erbitux (cetuximab) colorectal cancer drug in Japan this year. The Merck Serono expansion in Japan comes at a time other foreign drug makers are cutting back on their operations in the country. (Click here for more - may require a subscription